Skip to main content
Clinical Trials/EUCTR2012-001131-31-DK
EUCTR2012-001131-31-DKActive, not recruitingPhase 1

Effekts of nebivolol on the nitric oxide system in patients with essentiel hypertension - NEBI

Department of Medical Research0 sites25 target enrollmentStarted: June 14, 2012Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
25

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • Men and women
  • Age 40-70 years
  • Ambulatory blood pressure > 135 mmHg systolic and/or 85 mmHg diastolic in daytime during amlodipine treatment with either 5 or 10 mg
  • Informed consent
  • Fertiel women must take contraception
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 25
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 25

Exclusion Criteria

  • Diabetes mellitus
  • eGFR < 30
  • Albuminuria > 1,5 g/L
  • Renografi indicating sekundary hypertension
  • clinical signs of pheoocromocyta eller abnormal p-metanefrin.
  • Clinical important signs of lung, heart, liver or thyroid disease l
  • Clinical important abnormalities in screening blood samples and ECG
  • Clinical important hypokalimia
  • Clinical important abnormalities in plasma calcium
  • Neplastic diseases
  • Alcoholabuse
  • Drug or medical abuse
  • Pregnancy or nursing
  • Intolerans towards nebivolol
  • Bloddonationwithin a month
  • Uacceptable side effects to amlodipine
  • Ambulatory BP above 170/105 mmHg on hightest dose amlodipine 10mg)

Investigators

Similar Trials

Effekts of nebivolol on the nitric oxide... | Clinical Trial